COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 3 of 3 for:    NSR-REP1

Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia (STAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03496012
Recruitment Status : Active, not recruiting
First Posted : April 12, 2018
Last Update Posted : February 24, 2020
Information provided by (Responsible Party):
NightstaRx Ltd, a Biogen Company

Brief Summary:
The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of AAV2-REP1 in subjects with Choroideremia.

Condition or disease Intervention/treatment Phase
Choroideremia Genetic: AAV2-REP1 Phase 3

Detailed Description:
This is a phase 3 clinical trial of a gene therapy vector made from adeno-associated virus (AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be required to attend a screening visit during which their suitability for the study will be assessed, and eligible subjects will be randomized to either AAV2-REP1 treatment or the control group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 169 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group Study.
Masking: Single (Outcomes Assessor)
Masking Description:

Outcomes-assessors will be masked to whether the subject is in the treated or the control group.

Sponsor, subjects and trial centers are masked to dose.

Primary Purpose: Treatment
Official Title: A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
Actual Study Start Date : December 11, 2017
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AAV2-REP1 High Dose
Subjects will receive a single administration of high-dose AAV2-REP1 in one eye.
Genetic: AAV2-REP1
Sub-retinal injection of AAV2-REP1 after vitrectomy.

Experimental: AAV2-REP1 Low Dose
Subjects will receive a single administration of low-dose AAV2-REP1 in one eye.
Genetic: AAV2-REP1
Sub-retinal injection of AAV2-REP1 after vitrectomy.

No Intervention: Untreated control group

Primary Outcome Measures :
  1. Best Corrected Visual Acuity (BCVA) [ Time Frame: 12 Months ]
    Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart

Secondary Outcome Measures :
  1. Fundus autofluorescence (AF) [ Time Frame: 12 Months ]
    Change in AF (mm2)

  2. Optical coherence tomography (OCT) [ Time Frame: 12 Months ]
    Ellipsoid Zone

  3. Microperimetry [ Time Frame: 12 Months ]
    Change in Sensitivity (dB)

  4. Contrast Sensitivity [ Time Frame: 12 Months ]
    Pelli-Robson Chart

  5. Color Vision [ Time Frame: 12 Months ]
    Farnsworth-Munsell 100 Hue Test

  6. Reading Performance [ Time Frame: 12 Months ]
    International Reading Speed Texts

  7. Self Reported Vision-Targeted Health Status [ Time Frame: 12 Months ]
    25-item Visual Function Questionnaire (VFQ-25)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male subjects only.
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are willing and able to give informed consent for participation in the study.
  • Are male and ≥18 years of age.
  • Have a documented genetically-confirmed diagnosis of CHM.
  • Have active disease clinically visible within the macular region in the study eye.
  • Fulfill pre-defined visual acuity criteria.

Exclusion Criteria:

  • Have a history of amblyopia in the eligible eye.
  • Are unwilling to use barrier contraception methods, or abstain from sexual intercourse, for a period of 3 months, if treated with AAV2-REP1.
  • Have had previous intraocular surgery performed in the study eye within 3 months of Visit 1.
  • Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate in the study.
  • Have participated in another research study involving an investigational product in the past 12 weeks or received a gene/cell-based therapy at any time previously.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03496012

Layout table for location information
United States, California
Study Site
Los Angeles, California, United States, 90095
United States, Florida
Study Site
Miami, Florida, United States, 33136
United States, Maryland
Study Site
Baltimore, Maryland, United States, 21287
United States, New York
Study Site
New York, New York, United States, 10032
United States, Oregon
Study Site
Portland, Oregon, United States, 97232
United States, Texas
Study Site
Dallas, Texas, United States, 75231
United States, Wisconsin
Study Site
Madison, Wisconsin, United States, 53705
Study Site
Montréal, Canada, H3A 0E7
Study Site
Vancouver, Canada, V5Z 3N9
Study Site
Glostrup, Denmark
Study Site
Helsinki, Finland, 00290
Study Site
Montpellier, France
Study Site
Bonn, Germany, 53127
Study Site
Tübingen, Germany
Study Site
Nijmegen, Netherlands
United Kingdom
Study Site
Manchester, United Kingdom, M13 9WL
Study Site
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
NightstaRx Ltd, a Biogen Company
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: NightstaRx Ltd, a Biogen Company Identifier: NCT03496012    
Other Study ID Numbers: NSR-REP-01
2015-003958-41 ( EudraCT Number )
First Posted: April 12, 2018    Key Record Dates
Last Update Posted: February 24, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NightstaRx Ltd, a Biogen Company:
Gene Therapy
Timrepigene Emparvovec
Additional relevant MeSH terms:
Layout table for MeSH terms
Eye Diseases, Hereditary
Eye Diseases
Choroid Diseases
Uveal Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked